The Risky Research Review Act would establish the Life Sciences Research Security Board (LSRSB) as an independent executive-branch body. It would review proposed federal funding for life sciences research to determine if it is high-risk and whether funding should proceed.
The bill sets out a comprehensive framework—definitions, board composition, review procedures, and accountability—to manage biosafety and national security risks in life sciences funding.
At a Glance
What It Does
Creates the Life Sciences Research Security Board and endows it with binding authority to review and approve or block proposed federal funding for high-risk life sciences research before funds are awarded.
Who It Affects
Federal funding agencies (e.g., NIH, DoD, DOE), research institutions and labs receiving federal funds, biosafety officers, and researchers.
Why It Matters
Establishes a centralized, formal risk gate for sensitive life sciences funding, aiming to prevent dangerous research from moving forward while expanding federal oversight over potentially dual-use science.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a new Life Sciences Research Security Board (LSRSB) inside the Executive Branch. It defines what counts as high-risk life sciences research and dual-use research of concern, including categories of pathogens and toxins.
The LSRSB would review any federal funding proposal for life sciences research to decide whether the funding can proceed, and its determinations would be binding on the agency awarding the money. To operate, the Board would have nine board members plus an Executive Director, all subject to security clearances and ethics rules, and it would work with congressional and agency oversight to ensure accountability.
Before an agency can award federal funding for life sciences research, the proposal must be referred to the LSRSB for review. The entity seeking funding must attest, under penalty of perjury, whether the project constitutes high-risk life sciences research and disclose all sources of active funding if applicable.
The Board can request additional information and must certify the attestation. If the Board determines the project is high-risk, funding may be delayed or conditioned until the Board issues a final determination.
The Act also contemplates expedited review in emergencies, requires annual GAO audits, and sets aside funding to run the Board. The Board’s rules and procedures would be published and periodically updated, with ongoing congressional briefings and reporting.Implementation is phased: the Board must publish review procedures within 180 days of initial appointment and begin duties within 270 days of enactment.
Agencies must align pre-award and prepayment processes with the Board’s review to ensure compliance and auditability.
The Five Things You Need to Know
The bill creates the Life Sciences Research Security Board (LSRSB) as an independent executive-branch body.
Agencies must refer high-risk life sciences funding proposals to the LSRSB before funding and cannot award funds without its approval.
Entities seeking funding must attest to whether their project is high-risk and disclose active funding sources; the Board may request more information.
The Board includes an Executive Director and up to 25 staff, with accelerated security clearances for all members and staff.
The act authorizes $30 million annually (2026–2035) for LSRSB operations and mandates GAO audits and congressional oversight.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions for Life Sciences Research Security
This section defines key terms the Board will use. It sets out what counts as an agency, the Board, life sciences research, dual-use research of concern, high-consequence pathogens, and select agents or toxins. It also defines federal funding and outlines which congressional committees have oversight.
Establishment and membership
Creates the Life Sciences Research Security Board as an independent executive-branch body. It specifies appointment procedures, qualifications, term lengths, and limitations. It also imposes rules to avoid conflicts of interest and outlines restrictions on revolving-door relationships with defense or energy departments.
Board personnel
Details the position of Executive Director and supports staff. It covers appointment timing, security clearances, duties (liaison with Congress and agencies), and rules on compensation, staff qualifications, and conditional employment pending clearance checks.
Board mission and functions
States the Board’s mission as issuing binding determinations on federal funding for proposed high-risk life sciences research. It grants regulatory and procedural powers to establish review processes, handle classified information, and set up decision-making rules for lifecycle reviews, including expedited options during emergencies.
Agency procedures; referral to Board
Requires agencies to refer high-risk life sciences funding proposals to the Board before awarding funds. Establishes the mandatory attestation and certification process for entities applying for funding and sets out agency processes to maintain and share records with the Board.
Board review
Describes how the Board conducts reviews, the majority-vote standard for funding decisions, and the factors it must weigh (biosafety, biosecurity, public health, national security, international considerations, and risk-benefit trade-offs). Provides timelines for notifications to agencies and mechanisms for agency–Board meetings.
GAO Audits
Authorizes periodic GAO audits of the LSRSB to assess compliance, effectiveness, and efficiency of the review process and its impact on federal funding.
Funding
Authorizes a federal appropriation of $30,000,000 annually for fiscal years 2026 through 2035 to fund the Board’s operations and personnel.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal funding agencies (e.g., NIH, DoD, DOE) gain a clear, centralized risk framework that helps decide which high-risk projects to fund, reducing uncertain or dangerous investments.
- Universities, national labs, and private research entities receive a formal review channel that can protect sensitive projects while ensuring accountability and safety.
- Public health and national security communities benefit from rigorous assessment of high-risk research’s potential risks and mitigations.
- Congress and the Administration gain structured oversight and transparency through mandatory briefings, reporting, and GAO audits.
- Agency biosafety and security offices gain standardized procedures for risk assessment and enforcement.
Who Bears the Cost
- Laboratories and universities face additional compliance costs and review steps prior to funding.
- Federal agencies incur administrative overhead to prepare and submit material for Board review and to implement Board determinations.
- Contractors and subawardees must track disclosures and maintain thorough records of funding sources and risk mitigations.
- Grant applicants may experience delays in funding decisions due to mandatory Board review and potential escalations in emergency scenarios.
- Security-clearance requirements add procedural costs and administrative burden for personnel and institutional partners.
Key Issues
The Core Tension
The central dilemma is whether to prioritize airtight, centralized control of high-risk life sciences research (to protect public health and national security) or to preserve agility and openness in scientific inquiry that can drive innovation and quickly address health crises.
The act creates a robust governance framework that centralizes risk assessment of life sciences research. That centralization improves biosafety and biosecurity, but it also introduces potential delays and administrative burdens for institutions and agencies.
A core tension is balancing rapid response to public health or national-security concerns with the need for careful, comprehensive risk analysis of research proposals and ongoing projects. The framework relies on classified or protected information at times, which could complicate transparency and timely decision-making.
There is also a risk of chilling effects if the review process deters scientists from pursuing innovative high-reward work due to fear of non-compliance or onerous disclosures. While the Board’s binding authority provides strong leverage to prevent dangerous funding, it also concentrates power in a single body whose determinations may have far-reaching implications for scientific collaboration and timely medical or security breakthroughs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.